Skip to main content
DARE
NASDAQ Life Sciences

Dare Bioscience Details Imminent Product Launches and Path to Revenue in Updated Corporate Presentation

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.192
Mkt Cap
$32.506M
52W Low
$1.27
52W High
$9.19
52W Position info
73% above low
Off High info
76% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

DARE sits 73% above its 52-week low of $1.27 on light trading volume (0.3× avg).

Summary

Dare Bioscience released an updated corporate presentation detailing the imminent commercial launch of two products, Flora Sync LF5 and DARE to PLAY, marking its transition to a revenue-generating company.


Key Events · Product Development and Regulatory · DARE

  • Flora Sync LF5 Commercial Launch

    The company is targeting the commercial launch of Flora Sync LF5, a non-hormonal probiotic vaginal capsule, in June 2026, with expected product revenue.

  • DARE to PLAY Prescription Dispensing

    Prescription dispensing for DARE to PLAY (Sildenafil Cream) is targeted for Summer 2026, also contributing to first product revenue.

  • Positive Ovaprene Phase 3 Clinical Update

    The Data Safety Monitoring Board (DSMB) for the Ovaprene Phase 3 study recommended the study continue without modification in May 2026, indicating positive progress for this key pipeline asset.

  • Continued Non-Dilutive Funding

    The company highlighted over $75 million in non-dilutive funding awarded from institutions like the Gates Foundation, ARPA-H, and NIH, validating its development approach.


Analysis · DARE · Life Sciences

This 8-K filing, featuring an updated corporate presentation, outlines Dare Bioscience's transition to a commercial-stage company with two products expected to generate revenue in 2026. For a company that has previously faced 'going concern' warnings and Nasdaq delisting concerns, detailing concrete product launches (Flora Sync LF5 in June 2026 and DARE to PLAY in Summer 2026) and a clear path to revenue is a critical development. This strategic update provides a positive outlook on the company's financial viability and future growth, reinforcing investor confidence in its ability to overcome past challenges.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DARE was trading at $2.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.5M. The 52-week trading range was $1.27 to $9.19. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DARE - Latest Insights

DARE
Oct 06, 2026, 5:00 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.844
Real-time Price: $0.44501 info
Change: -$0.39899 (-47%) info
Market Cap: $8.849M info
DARE
Oct 02, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8428
Real-time Price: $0.44501 info
Change: -$0.39779 (-47%) info
Market Cap: $8.849M info
DARE
Sep 23, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.8074
Real-time Price: $0.44501 info
Change: -$0.36239 (-45%) info
Market Cap: $8.849M info
DARE
Aug 26, 2026, 5:15 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $0.810
Real-time Price: $0.44501 info
Change: -$0.36499 (-45%) info
Market Cap: $8.849M info
DARE
Aug 17, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.900
Real-time Price: $0.44501 info
Change: -$0.45499 (-51%) info
Market Cap: $8.849M info